Sanofi annual operating income
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sanofi Operating Income Growth & History (SAN)
Sanofi's operating income was €6.34B for fiscal 2025.
View full Sanofi company overviewSanofi annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €6.34B | −€908.0M | −12.52% |
| 2024 | 2024-12-31 | €7.25B | €292.0M | +4.20% |
| 2023 | 2023-12-31 | €6.96B | −€3.20B | −31.51% |
| 2022 | 2022-12-31 | €10.16B | €2.04B | +25.06% |
| 2021 | 2021-12-31 | €8.13B | −€5.99B | −42.42% |
| 2020 | 2020-12-31 | €14.11B | €11.06B | +362.57% |
| 2019 | 2019-12-31 | €3.05B | −€1.63B | −34.75% |
| 2018 | 2018-12-31 | €4.68B | −€1.13B | −19.43% |
| 2017 | 2017-12-31 | €5.80B | −€727.0M | −11.13% |
| 2016 | 2016-12-31 | €6.53B | €907.0M | +16.13% |
| 2015 | 2015-12-31 | €5.62B | — | — |
Sanofi quarterly operating income
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | €2.38B | €672.0M | +39.25% |
| Q1 2026 | 2026-03-31 | €2.27B | — | — |
| Q4 2025 | 2025-12-31 | €1.63B | — | — |
| Q3 2025 | 2025-09-30 | €3.79B | — | — |
| Q2 2025 | 2025-06-30 | €1.71B | — | — |
Sanofi operating income trends
Over the last five fiscal years, Sanofi's operating income decreased from €14.11B to €6.34B, a change of −€7.77B. The latest reported quarter, Q2 2026, shows €2.38B.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sanofi source filings ↗Community posts
Sanofi raises annual outlook as Dupixent drives double-digit sales growth
Sanofi ($SAN-EURONEXT) increased its 2026 outlook to low-teens sales growth and mid-teens growth in business earnings per share, both at constant exchange rates. Third-quarter 2026 sales reached €14.44 billion, increasing 14.3% on that basi ...
